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Can you diagnose this patient presenting with pneumonia and hypercapnic respiratory failure? 
http://bit.ly/2zz53zO
A 75-year-old woman was brought to the emergency 
department after she was found unconscious at 
her house. She had had a productive cough and 
fever up to 39°C for the previous 4 days. She had 
a past medical history of high blood pressure, 
paroxysmal atrial fibrillation and type 2 diabetes 
(without insulin therapy), and was regularly taking 
bisoprolol, propafenone, atorvastatin, metformin 
and aspirin. She was a nonsmoker and had no 
occupational exposures.
Physical examination showed tachypnoea, 
tachycardia (atrial fibrillation), normal blood 
pressure and transcutaneous arterial oxygen 
saturation decreased to 86% in room air. 
Auscultation of the lungs revealed diffuse wheezing 
and diminished breath sounds with mild dullness 
at the right base of the lung.
Blood tests showed: severe inflammation 
with white blood cell count 20.9×109 cells per L, 
neutrophils 17.2×109 cells per L and C-reactive 
protein 326.1 mg·L−1; elevated liver transaminases 
(alanine aminotransferase 3216 U·L−1 and aspartate 
aminotransferase 4359 U·L−1); and decreased 
kidney function (creatinine 313 µmol·L−1 and urea 
26.2 mmol·L−1). Arterial blood gas analysis showed 
severe hypercapnic respiratory failure with carbon 
dioxide tension (PaCO2) of 107 mmHg (14.3 kPa), 
oxygen tension (PaO2) of 63 mmHg (8.4 kPa), pH 
7.04 and HCO3− 28.9 mmol·L−1.
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Task 1
What diagnostic test would assist in the 
diagnosis?
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Chest CT was performed (figure 1), and showed 
pulmonary oedema and right-sided infiltrates 
characteristic of aspiration pneumonia. A diagnosis 
of right-sided aspiration pneumonia was established 
and antibiotic therapy with intravenous piperacillin/
tazobactam was initiated, due to severe infection 
and relatively high rates of antibiotic resistance in 
our country.
Due to the patient’s unconscious state, severe 
hypercapnic respiratory failure, and coexistent liver 
and kidney damage, the patient was intubated, 
mechanically ventilated and transferred to the 
intensive care unit (ICU).
During the next few days, the patient’s overall 
status improved, she regained consciousness and 
her laboratory tests returned to normal. Cultures 
from bronchoalveolar lavage were positive for 
Haemophilus influenzae.
Arterial blood gas analysis showed persistent 
hypercapnic respiratory failure (PaCO2 71 mmHg 
(9.5 kPa), PaO2 85 mmHg (11.3 kPa), pH 7.34 
and HCO3− 38.3 mmol·L−1). Due to prolonged 
mechanical ventilation, tracheostomy was 
performed.
After 15 days, mechanical ventilation was 
discontinued and the patient was breathing 
spontaneously through the tracheostomy tube. 
The only symptoms that remained were dyspnoea 
and mild weakness. Due to hypercapnia, pressure 
support ventilation was continued.
Multiple attempts to evacuate the tracheostomy 
tube were unsuccessful due to severe shortness of 
breath, stridor and acute respiratory insufficiency. 
During bronchoscopy, tracheal dyskinesia and 
bilateral vocal cord paresis were visualised. CT of the 
head and chest showed no major cerebrovascular or 
mediastinal pathology; there was no recent history 
of surgery or trauma.
Task 2
What would be the most appropriate 
treatment of respiratory failure in this case?
a) Supplemental oxygen with nasal cannula
b)  High-flow supplemental oxygen with 
nonrebreather mask
c) Noninvasive ventilation
d) Invasive mechanical ventilation
Answer 2
d) Invasive mechanical ventilation
Task 3
What pathology would you suspect in this 
patient?
Answer 1
Chest radiography or computed tomography 
(CT)
Figure 1 Chest CT.
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Due to persistent hypercapnic respiratory 
failure, bilateral vocal cord paresis and dysphagia, 
a neuromuscular pathology was suspected. 
Repeat neurological examination revealed a slight 
muscular weakness in the proximal leg muscles and 
fatigability of the extraocular muscles.
Myasthenia gravis was suspected, with critical 
illness polyneuropathy and Guillain–Barré syndrome 
being probable differential diagnoses.
AChR antibodies were negative. The patient 
was not tested for MuSK antibodies due to lack 
of availability at that time. RNS studies were 
performed and showed a decremental muscle 
electrical response (up to 20%) consistent with 
myasthenia gravis.
The patient was diagnosed with myasthenia 
gravis, and treatment with pyridostigmine 
150 mg·day−1 and prednisolone 5 mg·day−1 
(dosing gradually increased to 45 mg·day−1) was 
initiated. After a few days of treatment, the patient’s 
status greatly improved, dyspnoea and difficulty 
breathing disappeared, and hypercapnia resolved, 
with PaCO2 returning to normal. After a few weeks, 
the patient was active and capable of all self-care. 
Multiple attempts to evacuate the tracheostomy 
tube were unsuccessful (due to tracheal dyskinesia 
and bilateral vocal cord paresis); a permanent 
tracheostomy tube was placed and the patient 
was discharged.
Discussion
Neuromuscular respiratory failure (NRF) is the most 
serious complication of neuromuscular disorders. 
Prompt recognition of NRF and determination 
of the cause are essential. When the cause of 
NRF cannot be identified and the diagnosis on 
discharge remains unknown, outcomes are usually 
poor with high rates of severe disability. Among 85 
adults admitted to the ICU with acute NRF over 
a 6-year period, the most frequent causes were 
myasthenia gravis (myasthenic crisis), Guillain–
Barré syndrome, myopathies and amyotrophic 
lateral sclerosis (27, 12, 12 and 12 patients, 
respectively) [1]. Respiratory failure is rarely the 
presenting feature of a neuromuscular disorder. 
More often, it results from disease progression 
or exacerbation by a superimposed respiratory 
disease when the compensatory mechanisms are 
overwhelmed [2].
Myasthenia gravis, the most common disorder 
of neuromuscular transmission, is an autoimmune 
disease in which autoantibodies bind to AChR or 
other functionally related molecules and impair 
transmission in the postsynaptic membrane at 
the neuromuscular junction [3]. Most patients 
(80–90%) have antibodies AChR; approximately half 
of those without AChR antibodies have antibodies 
directed to MuSK. Patients without detectable 
AChR or MuSK antibodies are referred to as having 




What tests should be performed to confirm 
the diagnosis?
Answer 4
Nerve conduction studies with repetitive 
nerve stimulation (RNS) or single-fibre 
electromyography (SFEMG), acetylcholine 
receptor (AChR) antibodies, and antibodies 
against muscle-specific kinase (MuSK)
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The annual incidence of myasthenia gravis is 
approximately 8–10 cases per million and the 
prevalence is about 150–250 per million [5].
The main clinical feature is fluctuating weakness 
and fatigability of the skeletal muscles, which is the 
sole manifestation of the disease. Weakness can be 
generalised or confined to ocular muscles, resulting 
in ptosis and/or diplopia, which is the classic initial 
presentation of myasthenia gravis. About half of the 
patients presenting with ocular myasthenia gravis 
will develop generalised disease within 2 years. Other 
frequently involved muscle groups include bulbar, 
facial, neck and limb muscles with predominantly 
proximal weakness. Respiratory muscles can also be 
involved, producing the most serious symptoms of 
myasthenia gravis. It is usually seen with advanced 
disease and respiratory failure is rarely the initial 
presentation of myasthenia gravis [3, 6].
Diagnosis is based on clinical and serological 
testing, as well as electrophysiological tests. The 
presence of AChR or MuSK antibodies on serological 
assays provides the laboratory confirmation 
of myasthenia gravis [6]. The most commonly 
used electrophysiological test, due to its wide 
availability, is RNS, in which a motor nerve of a 
muscle is stimulated and the compound muscle 
action potential (CMAP) amplitude of that muscle is 
recorded. In myasthenia gravis, there is a progressive 
decline in the CMAP amplitude with the first four 
to five stimuli (a decremental response). RNS is 
considered positive if the decrement is >10%. 
SFEMG, a more technically demanding and less 
widely available test than RNS, is the most sensitive 
clinical test for myasthenia gravis. In SFEMG, the 
action potentials of two muscle fibres innervated by 
the same axon are recorded. The variability in time 
of the second action potential relative to the first is 
called “jitter”. Disorders with impaired transmission 
at the neuromuscular junction, such as myasthenia 
gravis, will produce increased jitter [7].
The four main types of treatment for  myasthenia 
gravis include symptomatic, chronic immunosup-
pressive and rapid immunomodulatory therapy, 
and thymectomy. The initial therapy for most 
patients with mild to moderate symptoms is with 
an acetyl cholinesterase inhibitor. Pyridostig-
mine is most commonly used. Neostigmine and 
ambenonium chloride are available, but are less 
effective than  pyridostigmine. If full clinical remis-
sion is not achieved with symptomatic therapy, 
immunosuppressive therapy with prednisone 
or a combination with azathioprine is added. 
 Mycophenolate mofetil is an alternative option, 
with methotrexate,  cyclosporine and tacrolimus 
being alternative secondary immunosuppressive 
drugs [3, 4, 8].  Rituximab might be a potential treat-
ment option for myasthenia gravis, with small case 
series showing substantial improvement in patients 
with insufficient response to prednisolone and 
 azathioprine [9]. In myasthenia gravis patients with 
thymoma, thymectomy should be performed, as it 
is associated with better outcomes [3]. In patients 
with severe worsening of muscle weakness involv-
ing the respiratory muscles and causing NRF, also 
termed myasthenic crisis, rapid therapy with plasma 
exchange or intravenous immune globulin is used, 
both having similar efficacy [10].
Any time there are difficulties weaning patients 
from mechanical ventilation due to neuromuscular 
pathology, critical illness polyneuropathy (CIP) must 
be considered. CIP is a symmetric distal axonal 
sensory–motor polyneuropathy affecting limb and 
respiratory muscles. It is a relatively common cause 
of neuromuscular weakness in critically ill patients 
in the ICU, along with critical illness myopathy. 
CIP is usually a consequence of severe sepsis and 
multiorgan failure or treatments required in the 
intensive care setting. It is usually discovered with 
difficulty in weaning a patient from mechanical 
ventilation that cannot be explained by pulmonary 
or cardiac pathology [11].
Contrary to myasthenia gravis, which is a 
classic autoantibody-mediated autoimmune 
disease, the pathogenesis of CIP is less well 
understood. Impaired microcirculation and 
mitochondrial function, and increased secretion 
of stress hormones, cytokines and nitric oxide 
during critical illness are probable mechanisms. 
Excitable tissues, such as peripheral nerves and 
muscle, require energy to maintain function, 
and are probably damaged by the combination 
of ischaemic and cytopathic hypoxia, resulting in 
axon degeneration [11, 12]. Reduction of nerve 
excitability by inactivation of sodium channels may 
also play a role [13].
The main clinical features of CIP are flaccid and 
symmetrical weakness that can range from mod-
erate paresis with reduced deep-tendon reflexes 
to severe quadriplegia with no deep-tendon 
reflexes, muscle wasting and hypotonia with or 
without involvement of respiratory muscles. The 
cranial nerves are usually spared. Distal and prox-
imal muscles are usually equally affected. Sensory 
impairment can also occur, with distal loss of pain, 
temperature and vibration senses [12, 14].
Findings on electrophysiological tests are 
consistent with primary axonal degeneration 
and show a reduction in CMAP and sensory 
nerve action potential amplitudes. Contrary to 
myasthenia gravis, there is no progressive decline 
in CMAP amplitude with repetitive stimulation (no 
decremental response) [12].
Whereas there are multiple treatment options 
in myasthenia gravis, no specific treatment has yet 
been effective in the case of CIP. Treatment is mainly 
supportive. Aggressive treatment of sepsis and early 
rehabilitation play an important role [14].
Here, we present a case report of a patient 
diagnosed with myasthenia gravis, presenting with 
bulbar dysfunction, bilateral vocal cord paresis and 
hypercapnic respiratory failure, which is rarely the 
initial presentation of the disease. There are a few 
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reports of bilateral vocal cord paresis and respiratory 
failure as an initial presentation of myasthenia 
gravis [15, 16]. In some cases of persistent bilateral 
vocal cord paresis due to myasthenia gravis, it is 
not possible to evacuate the tracheostomy tube 
and long-term (permanent) tracheostomy may be 
needed despite adequate treatment, as was the case 
with this patient [17].
Conclusion
Myasthenia gravis is a common cause of NRF, with 
CIP being the main cause of muscle weakness and 
NRF acquired in the ICU setting. Early recognition 
of NRF and its cause is important. Aggressive 
treatment of sepsis and early rehabilitation are 
essential and improve outcomes in CIP.
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